| http://purl.uniprot.org/citations/28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/28564605 | http://www.w3.org/2000/01/rdf-schema#comment | "Cancer patients having anti-programmed cell death-1 (PD-1)/PD ligand 1 (L1)-unresponsive tumors may benefit from advanced immunotherapy. Double-stranded RNA triggers dendritic cell (DC) maturation to cross-prime antigen-specific cytotoxic T lymphocytes (CTLs) via Toll-like receptor 3 (TLR3). The TLR3-specific RNA agonist, ARNAX, can induce anti-tumor CTLs without systemic cytokine/interferon (IFN) production. Here, we have developed a safe vaccine adjuvant for cancer that effectively implements anti-PD-L1 therapy. Co-administration of ARNAX with a tumor-associated antigen facilitated tumor regression in mouse models, and in combination with anti-PD-L1 antibody, activated tumor-specific CTLs in lymphoid tissues, enhanced CTL infiltration, and overcame anti-PD-1 resistance without cytokinemia. The TLR3-TICAM-1-interferon regulatory factor (IRF)3-IFN-β axis in DCs exclusively participated in CD8+ T cell cross-priming. ARNAX therapy established Th1 immunity in the tumor microenvironment, upregulating genes involved in DC/T cell/natural killer (NK) cell recruitment and functionality. Human ex vivo studies disclosed that ARNAX+antigen induced antigen-specific CTL priming and proliferation in peripheral blood mononuclear cells (PBMCs), supporting the feasibility of ARNAX for potentiating anti-PD-1/PD-L1 therapy in human vaccine immunotherapy."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.celrep.2017.05.015"xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/author | "Kataoka K."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/author | "Matsumoto M."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/author | "Ogawa S."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/author | "Takeda Y."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/author | "Yamagishi J."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/author | "Seya T."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/date | "2017"xsd:gYear |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/name | "Cell Rep"xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/pages | "1874-1887"xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/title | "A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy."xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://purl.uniprot.org/core/volume | "19"xsd:string |
| http://purl.uniprot.org/citations/28564605 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/28564605 |
| http://purl.uniprot.org/citations/28564605 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/28564605 |
| http://purl.uniprot.org/uniprot/#_P70671-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_Q0PM15-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_Q0PM16-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_A0A140LHE6-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_A0A140LI96-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_A0A1B0GRH7-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_A0A1B0GTA2-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_A0A140LJD9-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |
| http://purl.uniprot.org/uniprot/#_A0A140LJE8-mappedCitation-28564605 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/28564605 |